New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
09:25 EDTELGX, ELGX, ELGX, ARTC, ARTC, ARTC, BAXS, BAXS, BAXS, NVDQ, NVDQ, NVDQ, OXFD, OXFD, OXFD, FLDM, FLDM, FLDM, Q, Q, Q, ATRC, ATRC, ATRCPiper Jaffray's medtech analysts hold an analyst/industry conference call
The MedTech Analyst Team focuses on Piper Jaffray's covered universe from the perspective of Technical Analyst Johnson ahead of 1Q14 earnings results on an Analyst/Industry conference call to be held on April 11 at 10 am.
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
16:37 EDTOXFDOxford Immunotec selected to test new entrants for TB in UK national tender
Subscribe for More Information
November 19, 2015
08:45 EDTELGXEndologix to present 'positive' Nellix clinical data at VEITH Symposium
Subscribe for More Information
07:32 EDTELGXCanaccord to hold a forum
Subscribe for More Information
November 18, 2015
16:04 EDTELGXEndologix, TriVascular announce early termination of HSR waiting period
Subscribe for More Information
10:01 EDTELGXEndologix to host investor meeting
Investor meeting to be held in New York on November 19 at 6 pm. Webcast Link
07:41 EDTELGXEndologix announces start of physician-initiated registry of Nellix EVAS System
Endologix announced the start of a physician-initiated registry of the Nellix EndoVascular Aneurysm Sealing System, or Nellix EVAS System, used with aortic branch stent grafts for the treatment of patients with complex abdominal aortic aneurysms, or AAAs. The registry, to be conducted outside of the United States, will be called the ASCEND Registry. The primary investigators are Andrew Holden, MD, Associate Professor of Radiology at Auckland Hospital; and Professor Matthew Thompson, MD, Professor of Vascular Surgery, St. Georges Vascular Institute, London. The Nellix System received CE Mark in 2013 for the treatment of patients with infrarenal AAAs. The Nellix System is an investigational device in the United States.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use